Revlimid combo improves PFS by 25.3 months in Phase III for indolent lymphoma

Celgene Corp. (NASDAQ:CELG) reported additional data from the Phase III AUGMENT trial to treat relapsed or refractory follicular and

Read the full 199 word article

User Sign In